Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARQT Arcutis Biotherapeutics Inc.

Trading 02-04 12:58:40 EST

25.89

-0.30

-1.16%

High26.13	Low25.58	Vol1.35M
Open26.06	D1 Closing26.19	Amplitude2.10%
Mkt Cap3.17B	Tradable Cap2.28B	Total Shares122.49M
T/O34.82M	T/O Rate1.53%	Tradable Shares88.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARQT","market":"US","secType":"STK","nameCN":"Arcutis Biotherapeutics Inc.","latestPrice":25.885,"timestamp":1770227919314,"preClose":26.19,"halted":0,"volume":1346574,"delay":0,"changeRate":-0.011645666284841531,"floatShares":88242300,"shares":122492192,"eps":-0.350649,"marketStatus":"Trading","change":-0.305,"latestTime":"02-04 12:58:40 EST","open":26.06,"high":26.13,"low":25.58,"amount":34815518.607138,"amplitude":0.021,"askPrice":25.9,"askSize":208,"bidPrice":25.87,"bidSize":180,"shortable":3,"etf":0,"ttmEps":-0.350649,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"listingDate":1580446800000,"exchange":"NASDAQ","adjPreClose":26.19,"preHourTrading":{"tag":"盘前","latestPrice":26.1,"preClose":26.19,"latestTime":"08:44 EST","volume":271,"amount":7070.434444,"timestamp":1770212685548,"change":-0.09,"changeRate":-0.003436,"amplitude":0.029401},"postHourTrading":{"tag":"盘后","latestPrice":26.19,"preClose":26.19,"latestTime":"19:10 EST","volume":15867,"amount":415551.29,"timestamp":1770163811330,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.350249,"impliedVol":0.3536,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/ARQT","defaultTab":"news","newsList":[{"id":"2608618378","title":"Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream in Infants with Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608618378","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608618378?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037248,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. announced positive topline results from the INTEGUMENT-INFANT Phase 2 clinical trial evaluating ZORYVE  cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. The study showed that 58% of participants achieved a 75% improvement in the Eczema Area and Severity Index  at Week 4. ZORYVE cream was reported to be well tolerated, with a safety profile consistent with previous studies and no new safety signals identified through four weeks of treatment. The most frequently reported adverse events included diarrhea, nasopharyngitis, upper respiratory tract infection, and vomiting, with all adverse events described as mild to moderate. The company plans to submit a supplemental New Drug Application  for this age group in the second quarter of 2026. The results have already been announced in a company statement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7znzk8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4585","SG9999014021.USD","ARQT"],"gpt_icon":0},{"id":"2608986133","title":"Arcutis Biotherapeutics Inc - Plans to Submit Snda for Zoryve Cream in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608986133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608986133?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA9LY38L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2608861894","title":"Arcutis Biotherapeutics Inc: Investigational Zoryve Cream 0.05% Was Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861894?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA9LY38L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2608040869","title":"Arcutis Announces Positive Topline Results for Integument-Infant Phase 2 Trial of Zoryve® (Roflumilast) Cream 0.05% in Infants With Mild to Moderate Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608040869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608040869?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA9LY38L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2606222923","title":"Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606222923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606222923?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:30","pubTimestamp":1769470230,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcutis Biotherapeutics (ARQT – Research Report) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-arcutis-biotherapeutics-arqt-and-fisher-paykel-healthcare-corporation-limited-otherfspkf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-arcutis-biotherapeutics-arqt-and-fisher-paykel-healthcare-corporation-limited-otherfspkf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK8004","ARQT","LABU","XLV","BK4581","FPH.NZ","BK4139","BK4585","XBI","BK4588"],"gpt_icon":0},{"id":"2606242816","title":"Arcutis Biotherapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2606242816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606242816?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:32","pubTimestamp":1769445120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARQT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 11:32 ET (16:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2606246629","title":"Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606246629?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:23","pubTimestamp":1769437419,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics  said Monday it terminated its promotion agreement for Zoryve with Kowa Pharmaceuticals America on Friday.The agreement covered sales and promotion of the Zoryve cream by Kowa to pediatricians and primary care physicians in the US, according to the company.Arcutis said it now intends to oversee sales and promotion of Zoryve itself in the pediatric and primary care settings, as Kowa will now halt all activities of the cream, while the company will not be entitled to pay any further payments.Arcutis also said it anticipates to remain cash flow breakeven and expects no negative impact from this change on its 2026 net product sales outlook.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2606435432","title":"Arcutis Biotherapeutics announces termination of promotion agreement with Kowa","url":"https://stock-news.laohu8.com/highlight/detail?id=2606435432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606435432?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:16","pubTimestamp":1769433381,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America mutually agreed to terminate their ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-announces-termination-of-promotion-agreement-with-kowa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-biotherapeutics-announces-termination-of-promotion-agreement-with-kowa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2606329248","title":"Arcutis Biotherapeutics Inc - Kowa to Cease All Sales and Promotions of Zoryve","url":"https://stock-news.laohu8.com/highlight/detail?id=2606329248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606329248?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUA4B8RYN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2606248535","title":"Arcutis Biotherapeutics Inc - to Assume Sales and Promotion of Zoryve","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606248535?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:00","pubTimestamp":1769432402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nTUA4B8RYN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2605285751","title":"Is It Time To Reassess Arcutis Biotherapeutics (ARQT) After A 96% One Year Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605285751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605285751?lang=en_us&edition=fundamental","pubTime":"2026-01-24 02:41","pubTimestamp":1769193681,"startTime":"0","endTime":"0","summary":"If you are wondering whether Arcutis Biotherapeutics at US$26.65 is pricing in too much optimism or still leaving room on the table, the starting point is understanding what the market might already be expecting.\nThe share price return sits at 1.1% over the last 7 days, with a 9.1% decline over 30 days, an 8.1% decline year to date, but a 96.0% return over 1 year and 65.5% over 3 years, which suggests sentiment around risk and potential has shifted over different time frames.\nRecent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/is-it-time-to-reassess-arcutis-biotherapeutics-arqt-after-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/is-it-time-to-reassess-arcutis-biotherapeutics-arqt-after-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4139","ARQT"],"gpt_icon":0},{"id":"2605198107","title":"Arcutis announces results of survey on inflammatory skin conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2605198107","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605198107?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:15","pubTimestamp":1769001348,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics (ARQT) announced results of Skin Insights: Steroid Perceptions in Chronic Inflammatory Skin Diseases, a nationwide survey o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arcutis-announces-results-of-survey-on-inflammatory-skin-conditions-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arcutis-announces-results-of-survey-on-inflammatory-skin-conditions-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2603988093","title":"BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988093","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988093?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484217,"startTime":"0","endTime":"0","summary":"BTIG analyst Kambiz Yazdi maintained a Buy rating on Arcutis Biotherapeutics today and set a price target of $31.00. Yazdi covers the Healthcare se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-arcutis-biotherapeutics-arqt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-arcutis-biotherapeutics-arqt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT"],"gpt_icon":0},{"id":"2603575021","title":"Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603575021?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:37","pubTimestamp":1768271850,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $37.00. Ear covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-arcutis-biotherapeutics-arqt-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-arcutis-biotherapeutics-arqt-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","MFG"],"gpt_icon":0},{"id":"2602548512","title":"BRIEF-Arcutis Highlights 2026 Strategic Priorities And Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548512","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:26","pubTimestamp":1768224370,"startTime":"0","endTime":"0","summary":"BRIEF-Arcutis Highlights 2026 Strategic Priorities And Anticipated MilestonesJan 12 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O:ARCUTIS HIGHLIGHTS 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTON","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5RYCPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"2602510885","title":"Arcutis Biotherapeutics Projects 2026 ZORYVE Sales of $455-$470 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510885","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510885?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222830,"startTime":"0","endTime":"0","summary":"Arcutis Biotherapeutics Inc. has issued financial guidance for 2026, projecting full-year net product sales of ZORYVE  in the range of $455 to $470 million. This forecast reflects the company’s expectation of continued strong growth for ZORYVE, following a transformative year in 2025 in which the product solidified its position in the market for chronic inflammatory skin diseases. The transition to positive cash flows will enable Arcutis to further invest in expanding the ZORYVE franchise and advancing its pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the informati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLb2ZN58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","SG9999014039.USD","ARQT","BK4112","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2602510205","title":"Arcutis Biotherapeutics Inc - Topline Results From Integument-Infant Phase 2 Study Expected Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510205?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5RYCPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARQT"],"gpt_icon":0},{"id":"2602510878","title":"Press Release: Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510878?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"-- Continued strong growth of ZORYVE  in 2026 with full-year. -- Advancement of ZORYVE indication-expansion strategy beginning with. ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis. -- Transition to positive cash flows enables investment to both accelerate. \"2025 was a transformative year as we solidified ZORYVE's position as an advanced targeted topical with the potential to redefine the standard of care for chronic inflammatory skin diseases,\" said Frank Watanabe, president and chief executive officer of Arcutis. \"In 2026, we will build on this momentum by driving ZORYVE growth across approved indications and investing in our commercial capabilities to accelerate the conversion from topical corticosteroids. At the same time, we will advance our innovative pipeline, including ZORYVE life cycle initiatives and ARQ-234, our biologic for atopic dermatitis. With strong operating leverage, we are well positioned to pursue new opportunities and reinforce our leadership ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","ARQT","R","BK4139"],"gpt_icon":0},{"id":"2601330280","title":"Will ZORYVE-Driven 121.7% Revenue Growth Recast Arcutis Biotherapeutics' (ARQT) Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601330280","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601330280?lang=en_us&edition=fundamental","pubTime":"2026-01-08 10:45","pubTimestamp":1767840340,"startTime":"0","endTime":"0","summary":"In recent days, Arcutis Biotherapeutics reported revenue growth of about 121.70%, reflecting strong momentum in its dermatology portfolio led by ZORYVE for plaque psoriasis and atopic dermatitis.\nThis rapid expansion in dermatology revenue, alongside supportive analyst sentiment despite ongoing operating losses, highlights how ZORYVE is becoming central to Arcutis’ business profile.\nWe’ll now examine how this very large revenue increase and growing ZORYVE traction may influence Arcutis...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/will-zoryve-driven-1217-revenue-growth-recast-arcutis-biothe","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/will-zoryve-driven-1217-revenue-growth-recast-arcutis-biothe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARQT"],"gpt_icon":0},{"id":"2601823853","title":"Patrick Burnett, Officer, Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601823853","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601823853?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:47","pubTimestamp":1767826038,"startTime":"0","endTime":"0","summary":"Patrick Burnett, an officer of Arcutis Biotherapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2bF09v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Patrick Burnett, Officer, Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARQT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcutis.com","stockEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0969},{"period":"3month","weight":0.0742},{"period":"6month","weight":0.8548},{"period":"1year","weight":1.0638},{"period":"ytd","weight":-0.0981}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.076618},{"month":2,"riseRate":0.857143,"avgChangeRate":0.206175},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027279},{"month":4,"riseRate":0.5,"avgChangeRate":0.042439},{"month":5,"riseRate":0.5,"avgChangeRate":-0.104728},{"month":6,"riseRate":0.833333,"avgChangeRate":0.06903},{"month":7,"riseRate":0.666667,"avgChangeRate":0.023968},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019179},{"month":9,"riseRate":0.5,"avgChangeRate":-0.050429},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.153349},{"month":11,"riseRate":0.5,"avgChangeRate":0.146122},{"month":12,"riseRate":0.666667,"avgChangeRate":0.153171}],"exchange":"NASDAQ","name":"Arcutis Biotherapeutics Inc.","nameEN":"Arcutis Biotherapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcutis Biotherapeutics Inc.,ARQT,Arcutis Biotherapeutics Inc.股票,Arcutis Biotherapeutics Inc.股票老虎,Arcutis Biotherapeutics Inc.股票老虎国际,Arcutis Biotherapeutics Inc.行情,Arcutis Biotherapeutics Inc.股票行情,Arcutis Biotherapeutics Inc.股价,Arcutis Biotherapeutics Inc.股市,Arcutis Biotherapeutics Inc.股票价格,Arcutis Biotherapeutics Inc.股票交易,Arcutis Biotherapeutics Inc.股票购买,Arcutis Biotherapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcutis Biotherapeutics Inc.(ARQT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcutis Biotherapeutics Inc.(ARQT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction